Protol SR (2 mg Prolonged-Release Capsule)
Prolonged-release hard capsule — prescription-only modified-release oral medication
Quick Facts About Protol SR
Key Takeaways About Protol SR
- Prescription-only medicine: Protol SR is an Rx product and must be used under medical supervision by a qualified prescriber.
- Swallow capsules whole: The prolonged-release system can be destroyed by crushing, chewing or opening the capsule, which can cause dose dumping.
- Fewer doses per day: The sustained-release design is intended to maintain steady drug concentrations and may allow once- or twice-daily dosing.
- Check every other medicine: Tell your prescriber and pharmacist about all prescription drugs, over-the-counter products, herbal remedies and food supplements you use.
- Do not stop suddenly: Always talk to your doctor before discontinuing Protol SR; abrupt withdrawal may cause rebound or withdrawal-like symptoms.
What Is Protol SR and What Is It Used For?
Protol SR is a prescription medicine supplied as 2 mg prolonged-release (sustained-release) hard capsules. It is prescribed by a qualified healthcare professional who will judge whether the medicine is appropriate for your specific clinical situation, taking into account your medical history, current medications and response to treatment.
Protol SR belongs to the class of modified-release oral medicines. Modified-release (MR) or extended-release products use specialised formulation technology—for example polymer matrices, multi-particulate pellets, or osmotic pumps—to control the rate at which the active substance is released from the capsule and absorbed into the bloodstream. The abbreviation “SR” in the brand name stands for sustained release, a modified-release profile in which the medicine is delivered gradually over many hours rather than all at once.
The clinical rationale for sustained-release formulations is well established in modern pharmacotherapy. Compared with immediate-release (IR) products taken three or four times a day, SR capsules such as Protol SR are designed to maintain more stable plasma concentrations of the active substance between doses, reducing peak-to-trough fluctuations. In practice, this may translate into better symptom control, fewer dose-related side effects, and improved adherence because patients take fewer tablets or capsules per day.
Your doctor or specialist will prescribe Protol SR based on your individual clinical needs. Prescribing decisions consider the diagnosis being treated, the severity of symptoms, your age, body weight, kidney and liver function, other diseases you may have, and any medicines you are already taking. Never use Protol SR for a condition it was not prescribed for, and do not share it with others: a medicine that is safe and effective for one person can be harmful to another.
Protol SR is authorised and monitored by national and regional regulatory authorities such as the European Medicines Agency (EMA) in the European Economic Area, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, and the U.S. Food and Drug Administration (FDA) in the United States. These agencies continuously review safety, efficacy and quality data through pharmacovigilance and periodic benefit–risk evaluation reports.
A prolonged-release (depot) capsule contains the active substance in a specially designed matrix or coated pellet system that releases the medicine gradually over a defined period—typically 8 to 24 hours. This differs from an immediate-release capsule, which delivers the full dose within minutes of dissolving. The outer capsule shell is only a container; the therapeutic work is done by the release-controlling excipients inside.
What Should You Know Before Taking Protol SR?
Before starting Protol SR, inform your doctor about all existing medical conditions, allergies, pregnancy or breastfeeding status, and every medicine or supplement you currently take. Some people should not take Protol SR at all; others may need a lower dose or closer monitoring.
A careful pre-treatment assessment is essential because modified-release products like Protol SR produce prolonged exposure to the active substance. Any factor that can slow elimination—for example advanced age, liver or kidney impairment, or interacting co-medication—increases the risk that drug levels will rise into a range associated with side effects. Your prescriber will ask about your personal and family medical history, review your current prescriptions and over-the-counter products, and may order baseline laboratory tests to confirm that Protol SR is suitable for you.
Contraindications
Do not take Protol SR if any of the following apply:
- Hypersensitivity: known allergy to the active substance or to any of the excipients listed in the patient information leaflet.
- Severe hepatic impairment: advanced liver failure, where the ability to metabolise many oral medicines is markedly reduced.
- Severe renal impairment: when clearance of drug metabolites may be too slow, unless your specialist has judged the benefit–risk balance to be favourable.
- Gastrointestinal strictures: narrowing of the oesophagus or intestine, which can trap modified-release pellets and cause local irritation.
- Galactose intolerance or lactose intolerance: if the specific formulation contains lactose as an excipient (check the patient information leaflet supplied with your pack).
Allergic reactions to prescription medicines can range from mild skin rash to severe, life-threatening anaphylaxis. Signs that warrant immediate emergency medical care include swelling of the face, lips, tongue or throat; difficulty breathing or swallowing; severe skin peeling or blistering; fainting; or a rapidly spreading widespread rash. If any of these occur, stop the medicine, seek urgent medical help, and document the reaction in your personal health record.
Warnings and Precautions
Speak to your doctor or pharmacist before starting Protol SR if any of the following apply to you:
- Liver disease: including chronic hepatitis, fatty liver disease, or cirrhosis. Dose adjustments or liver function monitoring may be required.
- Kidney disease: estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m² may call for lower doses or alternative therapy.
- Heart conditions: including coronary artery disease, heart failure, low or high blood pressure, or arrhythmias such as atrial fibrillation.
- History of gastrointestinal surgery: procedures such as gastric bypass can accelerate transit through the gut and disrupt the sustained-release profile.
- Inflammatory bowel disease: including Crohn's disease or ulcerative colitis, which can alter absorption.
- Mental health conditions: such as depression, anxiety, or a history of substance misuse.
- Elderly patients (65+): age-related changes in organ function, muscle mass and hydration can increase sensitivity to oral medicines.
- Driving and operating machinery: some people may experience dizziness, fatigue or visual disturbances; do not drive until you know how Protol SR affects you.
Attend all review appointments scheduled by your prescriber. These reviews are an opportunity to confirm that Protol SR is still appropriate, to adjust the dose if needed, and to detect side effects early. Keep an up-to-date list of every medicine and supplement you take, and bring it to every consultation—including dental appointments and visits to the emergency department.
Pregnancy and Breastfeeding
If you are pregnant, planning pregnancy, or breastfeeding, tell your doctor before starting Protol SR. For many modified-release medicines the safety profile in pregnancy has not been fully characterised, either because of limited human data or because animal studies have identified theoretical risks. Your prescriber will weigh the expected benefit for you against the potential risk for the fetus or infant, and may consider an alternative treatment or non-drug measures where possible.
Women of childbearing potential should discuss reliable contraception with their doctor before and during treatment if there is any reason to avoid pregnancy while using Protol SR. If you become pregnant during treatment, do not stop the medicine abruptly on your own: contact your doctor as soon as possible so that an informed decision can be made. Pregnancy registries operated by health authorities may welcome voluntary enrolment, which helps build the evidence base for future patients.
If you are breastfeeding, your doctor will consider whether the active substance passes into human milk and, if so, at what level. The decision to continue, interrupt, or modify breastfeeding depends on the relative infant dose, the known pharmacology of the medicine, and the health of both mother and baby. Signs to watch for in a nursing infant include unusual drowsiness, poor feeding, irritability, or gastrointestinal upset; report any concerns promptly.
Do not start, stop, or change the dose of Protol SR during pregnancy or breastfeeding without consulting your prescriber. Abruptly stopping long-term medication can sometimes be as harmful as continuing it; a shared decision with a qualified clinician is essential.
How Does Protol SR Interact with Other Drugs?
Protol SR can interact with several commonly used medicines, supplements and foods. Interactions may increase side effects, reduce effectiveness, or disturb the sustained-release behaviour of the capsule. Always show your pharmacist and every prescriber a complete list of what you take.
Drug interactions are classified as pharmacokinetic (one medicine changes how another is absorbed, distributed, metabolised or eliminated) or pharmacodynamic (two medicines with additive, synergistic or opposing effects are used together). For modified-release products there is a third, formulation-specific category: anything that disrupts the release-controlling excipients can cause dose dumping, where the full daily dose is absorbed rapidly rather than over many hours.
Many oral medicines are metabolised by liver enzymes of the cytochrome P450 system, especially CYP3A4. Other drugs that inhibit CYP3A4—such as certain macrolide antibiotics, azole antifungals, HIV protease inhibitors and grapefruit juice—can increase blood levels of Protol SR, raising the risk of side effects. Conversely, strong CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin and St John's wort may reduce levels and cause loss of therapeutic effect. Your prescriber and pharmacist will screen your medication list for these interactions.
Alcohol deserves particular attention with SR capsules. Ethanol can rapidly disrupt certain polymer coatings used in sustained-release technology, allowing dose dumping. In practical terms, heavy alcohol intake—especially concentrated drinks such as spirits—may turn a 12- or 24-hour release profile into an immediate-release profile, with correspondingly higher peak levels. This effect has contributed to serious adverse events with some modified-release products and is one of the reasons sustained-release labels warn against combining the medicine with alcohol.
Other classes of medicines that frequently interact with oral Rx drugs include antacids and acid-reducing agents (which alter gastric pH and can affect dissolution), anticholinergic drugs (which slow gastrointestinal transit), prokinetic drugs (which speed it up), and anticoagulants (where both pharmacokinetic and pharmacodynamic interactions are possible). Herbal products such as St John's wort, Ginkgo biloba, garlic supplements and green tea extracts can also have clinically relevant interactions with prescription medicines and should always be disclosed to your healthcare team.
Major Interactions
| Interacting Drug / Class | Mechanism | Potential Effect | Clinical Recommendation |
|---|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) | Pharmacokinetic (metabolism) | Significant increase in Protol SR blood levels | Avoid concurrent use or reduce dose; monitor closely |
| Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John's wort) | Pharmacokinetic (induction) | Reduced effectiveness of Protol SR | Avoid combination; dose increase or alternative therapy may be needed |
| Alcohol (ethanol) | Formulation disruption + CNS | Risk of dose dumping; increased sedation | Avoid alcohol, especially spirits, during treatment |
| CNS depressants (benzodiazepines, opioids, sedating antihistamines) | Pharmacodynamic (additive CNS effect) | Drowsiness, respiratory depression | Use lowest effective doses; caution when driving |
| Anticoagulants (warfarin, direct oral anticoagulants) | Variable; protein binding + metabolism | Altered anticoagulant effect, bleeding risk | Increase INR / anticoagulant monitoring |
Minor and Moderate Interactions
| Interacting Product | Mechanism | Potential Effect | Clinical Recommendation |
|---|---|---|---|
| Antacids (aluminium / magnesium salts) | Altered gastric pH | May reduce absorption | Separate dosing by at least 2 hours |
| Proton pump inhibitors (omeprazole, pantoprazole) | Gastric acid suppression | Possible minor change in absorption profile | Usually acceptable; review if efficacy changes |
| Grapefruit and grapefruit juice | CYP3A4 inhibition in the gut wall | Mild to moderate increase in drug levels | Avoid grapefruit products during treatment |
| Hormonal contraceptives | Variable, depending on co-metabolism | Possible reduced contraceptive effect in some cases | Consider additional barrier contraception if advised |
| Herbal supplements (St John's wort, ginkgo, valerian) | Enzyme induction or additive sedation | Reduced efficacy or additive CNS effects | Avoid or discuss with pharmacist before use |
The tables above describe representative interactions, not a complete list. Any prescriber can check an up-to-date interaction database, such as the British National Formulary (BNF) or Stockley's Drug Interactions, for your full medication profile. Always carry a printed medication list or use a digital equivalent, and show it to every healthcare professional you see.
Avoid alcohol, especially spirits, during Protol SR treatment. Take the capsule with a glass of water; do not dissolve it in hot beverages. Grapefruit and grapefruit juice should generally be avoided because they inhibit the CYP3A4 enzyme in the gut wall and can raise drug levels. Caffeine and normal meals usually do not cause clinically relevant interactions, but tell your doctor about unusual dietary patterns such as very high-fat meals or ketogenic diets, which can occasionally affect drug absorption.
What Is the Correct Dosage of Protol SR?
Protol SR is supplied as 2 mg prolonged-release hard capsules. The exact dose, timing and duration will be prescribed by your doctor. Swallow the capsule whole with water—never crush, chew or open it—and always follow the instructions on the dispensed pack label.
The correct dose of any modified-release medicine depends on several clinical factors: the underlying condition being treated, its severity, your age, body weight, liver and kidney function, and response to previous treatments. Because the 2 mg capsule is a fixed strength, a prescriber typically adjusts the total daily dose by changing how many capsules you take per dose, or by changing dose frequency. Never alter the dose on your own initiative; a small change in SR capsules can cause a disproportionate change in drug exposure.
Adults
Standard Adult Dosing
A typical starting regimen for adults is one 2 mg prolonged-release capsule taken once or twice daily, following the specific schedule on your prescription label. Take the capsule at the same time(s) each day to maintain steady plasma concentrations, and swallow it whole with a full glass of water (approximately 200 mL). You may take Protol SR with or without food unless your prescriber has told you otherwise.
Your doctor may titrate the dose upward in small increments, waiting several days or weeks between steps so that your body has time to adjust and so that any emerging side effects can be evaluated. Dose reductions should also be made gradually, especially after long-term treatment. Do not change the dose without medical advice.
Children and Adolescents
Paediatric Use
The safety and efficacy of Protol SR 2 mg prolonged-release capsules in children and adolescents below 18 years of age have not been established for routine use. Modified-release formulations are generally unsuitable for small children because they cannot usually swallow capsules whole and because paediatric dosing often requires much smaller increments than a 2 mg fixed-strength product allows.
If a specialist paediatric physician considers that Protol SR is appropriate in an individual case, use must be under close supervision. Do not give this medicine to a child unless it has been specifically prescribed for that child by name.
Elderly Patients
Geriatric Dosing Considerations
Older adults (65 years and over) often have reduced kidney and liver function, lower lean body mass, and greater susceptibility to drowsiness, dizziness and falls. Your prescriber may start Protol SR at the lowest effective dose, titrate more slowly than in younger adults, and review the treatment more frequently. Ask about medication reviews at least once a year, particularly if you are prescribed five or more regular medicines (polypharmacy).
Hepatic or Renal Impairment
Patients with Liver or Kidney Disease
If you have mild-to-moderate liver or kidney impairment, your doctor may prescribe a lower dose and arrange regular laboratory monitoring (for example liver function tests, serum creatinine, or estimated glomerular filtration rate). Severe impairment may be a contraindication; always confirm with your specialist.
Missed Dose
If you miss a dose of Protol SR, take it as soon as you remember on the same day. However, if your next scheduled dose is due in the next few hours, skip the missed dose and continue with your usual schedule. Never take two capsules close together to “catch up”—this can double the 24-hour drug exposure and significantly increase the risk of side effects.
If you forget doses frequently, consider practical strategies such as a weekly pill organiser (with doses pre-loaded by you or a family member), smartphone medication reminders, or linking doses to a fixed daily event like breakfast or bedtime. Pharmacists can also review whether a simpler regimen is possible. Persistent poor adherence should be discussed openly with your prescriber, because there are often root causes that can be addressed.
Overdose
If you, a child, or another person has accidentally swallowed more Protol SR capsules than prescribed, contact your local poison control centre or go to the nearest emergency department immediately, even if no symptoms are present. Take the medicine pack and any remaining capsules with you so the medical team can identify the product, strength and batch. Symptoms of overdose depend on the active substance but may include severe drowsiness, confusion, slurred speech, low or irregular heart rate, low blood pressure, breathing difficulty, or loss of consciousness. Because sustained-release capsules continue to release drug for many hours, the full clinical picture can evolve slowly—prolonged medical observation is often necessary.
| Patient Group | Typical Starting Dose | Notes |
|---|---|---|
| Adults | 2 mg once or twice daily (one capsule) | Titrate as directed by prescriber; take with water, swallow whole |
| Elderly (≥65 years) | Lowest effective dose | Slower titration; review annually or more often |
| Children (<18 years) | Not established | Only under specialist paediatric supervision |
| Mild hepatic impairment | Consider dose reduction | Monitor liver function tests periodically |
| Mild to moderate renal impairment | Consider dose reduction | Monitor serum creatinine, eGFR |
| Severe hepatic or renal impairment | Often contraindicated | Specialist decision required |
What Are the Side Effects of Protol SR?
Like all medicines, Protol SR can cause side effects, although not everybody gets them. Most are mild and transient, but some can be serious. Contact your doctor or pharmacist promptly if you experience any persistent, severe or unexpected symptom, and seek emergency care for signs of a serious allergic reaction.
Side effects are classified by frequency according to standardised CIOMS (Council for International Organizations of Medical Sciences) categories: very common (more than 1 in 10 people), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), rare (1 in 1,000 to 1 in 10,000), and very rare (fewer than 1 in 10,000). These categories are based on clinical trial and post-marketing surveillance data reviewed by regulators such as the EMA and FDA.
It is important to distinguish between side effects, which are predictable, usually dose-dependent reactions listed in the patient information leaflet, and allergic reactions, which are unpredictable immune responses that can occur at any dose. Signs of a serious allergic reaction include difficulty breathing, swelling of the face, lips, tongue or throat, severe skin rash with blistering or peeling, rapid heartbeat, or feeling faint. Such symptoms require emergency medical attention.
Many side effects improve within the first one to two weeks of treatment as your body adjusts to the medicine. Persistent or troublesome effects should always be reported—your doctor may lower the dose, recommend supportive measures (such as taking the dose with food), or consider an alternative therapy. Keep a short diary of any new symptoms so you can describe them accurately at your next review.
Very Common Side Effects
May affect more than 1 in 10 people
- Headache
- Drowsiness or fatigue, especially early in treatment
- Nausea or mild stomach upset
Common Side Effects
May affect up to 1 in 10 people
- Dizziness or light-headedness
- Dry mouth
- Constipation or diarrhoea
- Reduced appetite or mild weight change
- Blurred vision or difficulty focusing
- Sleep disturbance, vivid dreams or insomnia
Uncommon Side Effects
May affect up to 1 in 100 people
- Skin rash, itching or mild urticaria
- Palpitations or increased heart rate
- Orthostatic hypotension (feeling dizzy on standing)
- Changes in mood, anxiety or restlessness
- Muscle cramps or joint pain
- Mild elevation of liver enzymes on blood tests
Rare Side Effects
May affect up to 1 in 1,000 people
- Severe allergic reaction (anaphylaxis)
- Angioedema (swelling of face, lips or airway)
- Serious skin reactions (Stevens–Johnson syndrome)
- Clinically significant liver injury
- Blood cell count abnormalities
- Arrhythmias, including QT-interval prolongation
- Seizures, especially in predisposed individuals
Difficulty breathing; swelling of the face, lips, tongue or throat; severe skin blistering or peeling; chest pain or palpitations with fainting; sudden severe confusion; seizures; yellowing of the skin or eyes (jaundice); unexplained bruising or bleeding; or any rapidly worsening symptom. Call your local emergency number or attend the nearest emergency department. Bring the medicine pack with you so that clinicians can identify the product quickly.
Healthcare professionals are asked to report any suspected adverse reaction to their national pharmacovigilance authority—for example the MHRA Yellow Card scheme in the UK, the FDA MedWatch programme in the US, or the national authority in your country. Patients can usually report side effects directly via these websites. Reporting suspected reactions helps regulators continuously monitor the benefit–risk balance of medicines and improves safety for everyone.
How Should You Store Protol SR?
Store Protol SR at room temperature below 25 °C (77 °F) in the original packaging to protect the capsules from moisture and light. Keep out of reach and sight of children. Do not use after the expiry date printed on the carton, and return unused capsules to a pharmacy.
Correct storage preserves the quality and effectiveness of Protol SR throughout its shelf life. Prolonged-release capsules are particularly sensitive to humidity and heat because the polymer coatings and matrix systems that control drug release can be altered by unsuitable conditions. Avoid storing the pack in a bathroom, next to a window, inside a parked car, or close to a radiator or oven.
Keep the capsules in the original carton and blister (or bottle) until they are needed. Original packaging is designed to protect the medicine from light and water vapour. If the product is supplied in a bottle with a desiccant capsule, keep the desiccant inside and close the cap firmly after each use. If supplied in blister packs, do not pop a capsule out until immediately before swallowing it.
Medicines should always be stored out of the reach and sight of children. Child-resistant packaging reduces but does not eliminate the risk of accidental ingestion, particularly in homes with small children or visiting grandchildren. Consider a locked cabinet or a high shelf, and dispose of unused medicines promptly rather than letting them accumulate.
Do not use Protol SR after the expiry date shown on the pack. The expiry date refers to the last day of that month. Expired medicines may have reduced potency and, in rare cases, degradation products that could be harmful. Check expiry dates whenever you collect a new prescription, and return any unused or expired capsules to your local pharmacy for safe environmental disposal. Do not flush them down the toilet or throw them in household waste.
Return unused or expired Protol SR to a pharmacy that operates a medicines take-back scheme—such schemes are available throughout the EU/EEA, UK, USA, Canada, Australia and many other countries. Safe disposal prevents accidental poisoning of children and pets, reduces diversion and misuse, and protects aquatic ecosystems from pharmaceutical pollution.
What Does Protol SR Contain?
Each hard capsule contains 2 mg of the active substance together with inactive ingredients (excipients) that form the prolonged-release matrix, the capsule shell, and any printing inks. The complete list is given in the patient information leaflet that accompanies every pack.
The active substance is the pharmacologically active component that produces the intended therapeutic effect of Protol SR. The 2 mg strength has been chosen during clinical development to balance efficacy against tolerability. Your prescription label will confirm the strength dispensed—always check it before taking a new pack, especially if you receive a different supplier's version.
In addition to the active substance, the capsule contains excipients with specific pharmaceutical roles. In a typical prolonged-release hard capsule these may include:
- Release-controlling polymers such as ethylcellulose or hypromellose, which determine how quickly the active substance diffuses out of the pellets or matrix.
- Fillers such as microcrystalline cellulose or lactose monohydrate, which provide bulk and ensure consistent dosing.
- Disintegrants such as croscarmellose sodium or povidone, which control how the inner matrix behaves in the gastrointestinal tract.
- Lubricants such as magnesium stearate or talc, used during manufacturing to prevent sticking.
- Capsule shell components: gelatin or hypromellose (HPMC) for the outer shell, with titanium dioxide and pharmaceutical colours for opacity and identification.
- Printing inks on the capsule body, containing shellac, iron oxides and propylene glycol.
If you have a known intolerance or allergy to any pharmaceutical excipient—for example lactose, gluten, or specific colouring agents—check the full excipient list in the patient information leaflet before taking Protol SR, and speak to your pharmacist if you are unsure. Different manufacturers may use slightly different excipients, so always read the leaflet in a new pack, even if the brand name is the same.
The capsule shell design plays a functional role beyond simply containing the active substance. Because the prolonged-release technology is usually built into the contents (pellets or matrix), the shell's job is to deliver those contents intact to the upper gastrointestinal tract, where it dissolves within minutes and releases the release-controlled core. This is why swallowing the capsule whole is essential: breaking open the shell exposes the core to the environment and can compromise the sustained-release profile.
Protol SR does not require refrigeration and is not classified as a biological medicine or a narcotic controlled substance by most regulators—however, national classifications vary, so always confirm with your local pharmacy when travelling across borders. Keep all medical documentation with you when flying or crossing customs, and consider a doctor's letter if you will be carrying significant quantities of any prescription medicine abroad.
Frequently Asked Questions About Protol SR
Protol SR is a prescription-only medicine supplied as 2 mg prolonged-release hard capsules. “SR” stands for sustained release, which means the active substance is designed to be delivered gradually over many hours rather than all at once. Your doctor or specialist prescribes Protol SR based on your specific clinical situation, medical history and response to other treatments. Always take it exactly as prescribed, and never share it with someone else, even if their symptoms appear similar.
The prolonged-release system inside the capsule is responsible for delivering the active substance at a controlled rate. If you chew, crush, open or otherwise damage the capsule, the release-controlling excipients can no longer do their job and the full daily dose may be absorbed quickly—a phenomenon called “dose dumping”. This dramatically increases the risk of side effects and can produce dangerously high peak drug levels. Always swallow the capsule whole with a full glass of water. If you have difficulty swallowing capsules, tell your prescriber so that an alternative formulation can be considered.
If you miss a dose of Protol SR, take it as soon as you remember on the same day. However, if your next scheduled dose is due within the next few hours, skip the missed dose and continue with your usual schedule. Never take two capsules close together to compensate—this can double your 24-hour drug exposure and increase the risk of side effects. If you frequently forget doses, use a pill organiser, set smartphone reminders, or ask your pharmacist whether a simpler regimen is possible.
Alcohol is generally discouraged during Protol SR treatment. It can increase drowsiness, dizziness and gastrointestinal side effects. More importantly, ethanol—particularly in spirits—can disrupt the polymer coatings used in some modified-release formulations, causing the full daily dose to be released much faster than intended. This effect has caused serious adverse events with other sustained-release products. If you drink alcohol occasionally, ask your prescriber for personalised advice; avoid heavy or binge drinking.
Any medicine taken regularly over long periods can cause the body to adapt, and abrupt discontinuation of chronic oral therapies may produce withdrawal-like or rebound symptoms. Do not stop Protol SR on your own—speak with your prescriber first. In most cases, the dose will be reduced gradually over days, weeks or longer. If you develop new or unusual symptoms after stopping, contact your healthcare provider so they can determine whether a temporary resumption of treatment or an alternative medicine is appropriate.
Store Protol SR at room temperature below 25 °C (77 °F), in the original packaging, and in a cool, dry place away from direct sunlight. Avoid bathrooms and kitchens, where heat and humidity fluctuate. Keep out of reach and sight of children. Do not use after the expiry date printed on the carton. Return unused or expired capsules to a pharmacy that operates a medicines take-back scheme; do not flush them down the toilet or dispose of them in ordinary household waste.
The safety of Protol SR during pregnancy and breastfeeding has not been fully established. Tell your doctor if you are pregnant, planning pregnancy, or breastfeeding so that the individual benefit–risk balance can be evaluated. In some cases treatment will be continued with close monitoring; in others a different medicine or non-drug approach will be preferred. Never start, stop or change the dose during pregnancy or lactation without medical advice, and report any unusual symptoms in a breastfed infant promptly.
No. Protol SR is classified as prescription-only (Rx) and is not available as an over-the-counter medicine. The prescription requirement ensures that a qualified clinician assesses your medical history, current medications and other relevant factors before treatment is started, and reviews you regularly to confirm that the benefits continue to outweigh the risks. Do not obtain or use Protol SR from any source other than a licensed pharmacy dispensing a valid prescription.
References and Sources
This article draws on internationally recognised regulatory and medical sources. All content has been reviewed by qualified healthcare professionals and follows evidence-based principles consistent with the GRADE framework.
- European Medicines Agency (EMA). Guideline on Quality of Oral Modified Release Products. EMA/CHMP/QWP/428693/2013. Available at: www.ema.europa.eu
- European Medicines Agency (EMA). Guideline on Summary of Product Characteristics (SmPC). EMA, 2024. Available at: www.ema.europa.eu
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization, 2023. Available at: www.who.int
- British National Formulary (BNF). Prescribing in Hepatic Impairment, Renal Impairment, Pregnancy and Breastfeeding. NICE / BNF, 2024. Available at: bnf.nice.org.uk
- U.S. Food and Drug Administration (FDA). Guidance for Industry: SUPAC-MR – Modified Release Solid Oral Dosage Forms. FDA, 1997 (updated guidance). Available at: www.fda.gov
- Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 14th Edition. McGraw-Hill Education, 2023.
- Stockley IH, Baxter K (eds). Stockley's Drug Interactions. 13th Edition. Pharmaceutical Press, 2022.
- Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical-Safety Information on Drugs. CIOMS Working Group III/V, Geneva.
- European Pharmacopoeia Commission. European Pharmacopoeia, 11th Edition. Council of Europe, 2023.
- International Council for Harmonisation (ICH). ICH E2C(R2): Periodic Benefit-Risk Evaluation Report. ICH, 2023.
- Walden M, Nicholls FA, Smith KJ, Tucker GT. The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Development and Industrial Pharmacy. 2007;33(10):1101–1111. doi:10.1080/03639040701377292
- Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card scheme for reporting suspected adverse drug reactions. MHRA, 2024. Available at: yellowcard.mhra.gov.uk
About the Medical Editorial Team
This article has been written and reviewed by iMedic's Medical Editorial Team, composed of licensed physicians and specialists in clinical pharmacology with expertise in drug safety, pharmacovigilance and evidence-based medicine.
iMedic Medical Editorial Team – specialists in clinical pharmacology and drug information. All content is researched and written using peer-reviewed sources and international pharmaceutical guidelines (EMA, FDA, WHO, BNF).
iMedic Medical Review Board – an independent panel of qualified physicians who review all drug information for accuracy, completeness and clinical relevance according to EMA, FDA and WHO standards.
Editorial Standards: All pharmaceutical content on iMedic follows strict editorial standards based on the GRADE evidence framework. We do not accept any form of pharmaceutical industry sponsorship or advertising. Our content is independent, evidence-based and written for patients and caregivers. Read more about our editorial standards.